have at most two subconductance states, and in NMDA receptors there is a negative allosteric coupling between the glycine (NR1) and glutamate (NR2) sites (for a recent review, see Erreger et al., 2004) . Therefore, we set out to determine whether the GluR2 paradigm of partial agonist action applies to NMDA receptors, first focusing on the NR1, glycine binding subunit. Previously, we showed that the NR1 ligand binding core has a structure similar to that of GluR2 (Furukawa and Gouaux, 2003) . However, on the basis of the first series of structures, we found that the partial agonist D-cycloserine yielded a domain closure that was similar to that of glycine, a result that we would not have predicted from the AMPA receptor paradigm. Because this single observation suggested that NMDA and AMPA receptors might conform to different models of partial agonist action, we investigated the structural and functional behavior of the NMDA receptor in the presence of a series of partial agonists.
Three cyclic homologs of glycine-1-aminocyclopropane-1-carboxylic acid (ACPC) soluble NR1 ligand binding core and carried out electrophysiological recordings on wild-type and NR1 mutants to measure the extent of ion channel activation fore, reflects the subtle differences between ACPC, and to test the significance of specific receptor-ligand ACBC, and cycloleucine. Indeed, the molecular volinteractions.
umes increase by only w11 Å 3 with the addition of each methylene group.
Results

NMDA Receptor Activation
To determine the efficacy of ACPC, ACBC, and cyclo-NR1 S1S2 Displacement Experiments NR1 S1S2 is the water-soluble, ligand binding core of leucine on NMDA receptor activation, we carried out the two-electrode voltage-clamp (TEVC) experiments the glycine binding NR1 subunit and is composed of polypeptide segments S1 and S2 (Furukawa and Gouusing NR1/NR2B subunits expressed in Xenopus oocytes. Shown in Figure 2 are records and graphical aux, 2003). ACPC, ACBC, and cycloleucine are amino acid derivatives with three-, four-, and five-membered summaries of the TEVC experiments. Here we assume that glycine is a full agonist and produces maximal recarbocyclic rings ( Figure 1A ). To determine the relative affinities of these compounds at the glycine site of the ceptor activation. ACPC and ACBC dose-dependently activate the NR1/NR2B NMDA receptor and yield maxi-NR1 receptor, we carried out radioligand displacement experiments using the competitive antagonist we wanted to show that the apparent partial agonist behavior of ACPC was not simply due to its antagonistlike action at the NR2B glutamate site. Therefore, we carried out experiments using an ACPC concentration at the "top" of the ACPC dose-response curve and either 0.1 mM or 1.0 mM glutamate. We found that increasing the glutamate concentration from 0.1 mM to 1.0 mM did not substantially alter the maximal current evoked by saturating concentrations of ACBC ( Figure  2C ), thereby indicating that the partial agonist activity of ACPC was not simply due to competitive antagonist action at the NR2B site. In agreement with the previous studies, our experiments showed that ACPC and ACBC are partial agonists and cycloleucine is a competitive antagonist at NR1/NR2B NMDA receptors (Watson and Lanthorn, 1990).
Crystallographic Analysis of NR1 S1S2 Complexes
To understand the molecular basis for the activity of ACPC, ACBC, and cycloleucine at NMDA receptors, we cocrystallized the NR1 S1S2 ligand binding core with each of the three compounds. As summarized in Table  1 , all of the crystals diffracted beyond 1.8 Å resolution, and the NR1 S1S2/ACPC complex diffracted particularly well, to 1.4 Å resolution. The crystal structures were solved by molecular replacement (MR), using the intact glycine bound structure as a search model for the ACPC and ACBC complexes. For the cycloleucine complex, the MR probes were domains 1 and 2 of the NR1 S1S2/glycine structure. The resulting MR solutions were then subjected to crystallographic refinement, as summarized in Table 2 . In the ACPC and ACBC bound structures, there are no electron density features for the four N-terminal and one C-terminal residues. The trace of the ACPC complex is continuous and includes loop 1 (residues 439-449), a region that was disordered in all previous NR1 S1S2 structures and that is also disordered in the ACBC and cycloleucine complexes. The continuous density for the NR1 S1S2/ACPC complex is probably due, at least in part, to the completeness of Arg523 on domain 1 and participates in hydrogen 3F ). Localized at the end of strand 12 and positioned ACBC and cycloleucine are similar to those made by ACPC ( Figures 3C-3E ). Nevertheless, there are imporbeneath the ligands, Trp731 "senses" the volume of the substituent attached to the α-carbon of the ligand. As tant differences between the complexes, and some of these differences include variations in the conformation the volume of the substituent increases, the indole of Trp731 moves "down" and away from the ligand bindof Ser688 and Val689 and the position of a key water molecule (W1) in the binding pocket. When comparing ing pocket, resulting in a change in the side chain χ 1 dihedral angle of 4.8°, 6.0°, and 10.0°in the ACPC, the glycine bound structure to the ACPC and ACBC complexes, the volume of the cavity occupied by the ACBC, and cycloleucine complexes, respectively. To illustrate that the indole of Trp "rides" along with the ligand increases from w56 Å 3 to 72 Å 3 and 116 Å 3 , respectively; the expansion of the cavity involves side ligand, we note that the closest contacts between ligands and the indole ring are 3.4, 3.5, and 3.5 Å in the chain reorientations and small shifts of side chain and main chain positions. For the cycloleucine complex, ACPC, ACBC, and cycloleucine complexes, respec- Phe484 is a key residue that "caps" the ligand bind-ing sites in NR1 S1S2. In AMPA receptors, the equivapartial agonists induce essentially the same degree of domain closure. Thus, the molecular mechanisms of lent residue is tyrosine, and the aromatic ring occupies a similar position as the aromatic ring of Phe484 in NR1.
partial agonist action at NMDA and AMPA receptors are distinct. In NR1 S1S2, as in GluR2 S1S2, the nonpolar portion of agonists, proximal to the α-carbon, participate in hydrophobic interactions with the aromatic ring, and the Partial Agonist-Induced Conformational Changes distances between the α-carbon of ACPC, ACBC, and A detailed comparison of the glycine, ACPC, and ACBC cycloleucine and the plane of the phenyl group are 3.3, complexes reveals that even though the three com-3.5, and 3.5 Å, respectively ( Figure 3F ). For NR1 S1S2, plexes have the same degree of domain closure, the however, the edge of Phe484 interacts with the indole partial agonist complexes differ in the conformation of of Trp731, forming a hydrophobic interdomain contact. 8 residues, from Thr749 to Ser756 on strand 14, located Thus, as the ring of the ligand expands, in going from at the hinge region of the "clamshell" which spans the ACPC to cycloleucine, and the binding pocket exparts of domains 1 and 2 ( Figure 5A ). As illustrated in pands, the hydrophobic interdomain interactions be- To define the separation of domains 1 and 2, i.e., the matic-aromatic contacts with Tyr692 in helix F ( Figure  5D ). In the glycine complex, these residues interact via extent of "domain closure," we superimposed domain 1 of two structures and then determined the transface-to-edge contacts (yellow), while in the ACPC and ACBC complexes the interaction is best described as formation required to superimpose domain 2. Using the glycine bound structure as a reference, we determined face-to-face contacts (green and blue, respectively). Because Phe754 is close to the agonist binding pocket the extent of domain closure for all of the available NR1 S1S2 structures. By plotting the extent of domain cloand appears to play a role in the conformational heterogeneity of the second interdomain β strand, we investisure versus maximal current, we determined the correlation between domain closure and ion channel activagated the functional consequences of changing Phe754 to a leucine (F754L) and an alanine (F754A). For the tion ( Figure 4C , 1996) . While the F754A mutation did not affect the extent of ACBC activation, the F754L mutation retures of the GluR2 S1S2 ligand binding core and have carried out complementary electrophysiological experiduced the efficacy of ACBC to 13.8%, relative to glycine. In addition, both mutations resulted in at least a ments, we also plot the structure and current data for GluR2 in Figure 4C . As evident from inspection of the 10-fold decrease in ACBC potency. Together, these results support the suggestion that F754 and its interacgraph, the relationships between domain closure and ion channel activation are different for NR1 and GluR2. tions with helix F play an important role in agonist binding and gating. For GluR2, partial agonists induce less domain closure than full agonists, i.e., domains 1 and 2 do not come Val689, at the base of helix F, is another residue that plays an important role in agonist-receptor interactions as close together, and full agonists induce the same extent of domain closure. By contrast, for NR1, full and as described above and that is near Phe754 and Tyr692. To examine the role of Val689 in partial agonist lyzed the noncovalent contacts between domain 1 and domain 2. As illustrated in Figure 6 , there are multiple recognition, we mutated the valine to an alanine (V689A) and found, remarkably, that in the context of sites of contact between domains 1 and 2 in both structures. However, in the NR1 structure there are more the V689A mutant, ACBC was nearly as efficient as glycine in promoting receptor activation. Therefore, we contacts between domain 1 and domain 2, and the two major contact sites are located on either side of the suggest that by truncation of the side chain at position 689, the larger ACBC agonist is now able to stabilize agonist binding pocket. In particular, for NR1 S1S2, Asn499, Gly485, and Lys483 on domain 1 form contacts the closed-cleft conformation of the ligand binding domain almost as well as glycine. However, the V689A with Gln686 and Glu712 on domain 2 via hydrogen bonds that are conserved among the full and partial mutation increases the EC 50 values for glycine (2.1-fold) and ACBC (16-fold), indicating that the mutation also agonist bound structures. Importantly, these polar residues are well defined by their respective electron denaffects relative apparent affinities (Figures 5E and 5F) .
sities, indicating that they tend to occupy a single conformational state ( Figure 6B ).
Interdomain Interactions in NR1 and GluR2 Ligand Binding Cores To better understand the interactions that are responsi-
The Cycloleucine-Bound NR1 S1S2 Forms a Dimer The cycloleucine bound NR1 S1S2 ligand binding core ble for stabilizing the NR1 S1S2 and GluR2 S1S2 ligand binding cores in closed-cleft conformations, we anaforms a back-to-back dimer that is similar to the GluR2 NR1, the equivalent residue is asparagine, and in the sity is a small anionic molecule, perhaps bearing two negative charges at each end of the molecule. NR1 S1S2 homodimer the primary amide group of the asparagine side chain makes a hydrogen bond with the backbone carbonyl of Leu774 on the 2-fold related proDiscussion tomer.
In electron density maps, we found nonprotein elecThe problem at hand concerns the conformational states that partial agonists induce in the NR1 subunit tron density in the dimer interface that is suggestive of one or more bound molecules and/or ions (Figure 7) . of the NMDA receptor and how these conformational states modulate the activity of the receptor. Two difThe dumbbell-shaped density is at the "top" of the dimer interface, is nestled between four lysine side ferent models for the conformational states induced by full and partial agonists are illustrated in Figure 8 depending on the specific stereochemical properties of the agonist, and that the extent of conformational the density is too large for one L-lactate molecule and too small for two. Thus, whereas the origin of the denchange in the agonist binding domain is correlated to the extent of receptor activation. sity is uncertain, a tentative conclusion is that the den-with at least two qualifications. First, we have only studied five full or partial agonists of the NMDA receptor by crystallography and electrophysiology; in the case of the GluR2 AMPA receptor, we have examined over ten full and partial agonists. Second, the NR1 S1S2 structures with full and partial agonists are derived from the same crystal form, and it is possible that lattice contacts, and not inherent properties of the ligand binding domain, stabilize a single closed-cleft conformation in the presence of both full and partial agonists. While this is a valid concern, there are three reasons why lattice forces are unlikely to be responsible for the conformational behavior of NR1 S1S2: (1) the lattice does not restrict the conformational rearrangement of the second interdomain β strand, and thus we know that the molecule is not entirely "frozen" in the crystal lattice; (2) cocrystallization experiments did not reveal new conditions or crystal forms for the partial agonists, thus suggesting that the partial agonist complexes adopt a similar conformation, in solution, as the full agonist complexes; (3) the GluR2 S1S2 construct readily undergoes domain movements to a modest extent (w3.5°) in the crystal lattice upon exchange of full and partial agonists in the crystal ( While this conclusion is striking, it must be tempered of the volume of specific amino acid side chains, and In addition, however, it is likely that the conformational stability and dynamical behavior of the polypeptide and we know from studies on GluR2 S1S2 and NR1 S1S2 that the clamshell hinge passes through the secmain chain, in the regions of the interdomain β strands, will also play an important role in determining the staond interdomain β strand, we suggest that the ACPC and ACBC closed-clamshell states are less stable than bility of the clamshell at various degrees of domain closure ( tion of the respective PEGs was simply increased to 30% and 24%, respectively, while for the cycloleucine complex 18% glycerol was
